| Name | Title | Contact Details |
|---|
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Our proprietary mRNA therapeutic platform (MRTTM) is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. We believe that our MRTTM platform is applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease, including diseases that affect the lung, liver, eye, central nervous system, lymphatic system and circulatory system. Our two lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency.
Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients` lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug`s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana`s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today`s cancer treatments.
REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world`s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. We have one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which prevents viral entry into healthy T-cells by blocking the HIV co-receptor CCR5. The drug candidate is also being tested for other immunological conditions, and has been granted FDA orphan drug status for the treatment of Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation.